RV144 HIV-1 vaccination impacts post-infection antibody responses

The RV144 vaccine efficacy clinical trial showed a reduction in HIV-1 infections by 31%. Vaccine efficacy was associated with stronger binding antibody responses to the HIV Envelope (Env) V1V2 region, with decreased efficacy as responses wane. High levels of Ab-dependent cellular cytotoxicity (ADCC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mdluli, Thembi, Jian, Ningbo, Slike, Bonnie, Paquin-Proulx, Dominic, Donofrio, Gina, Alrubayyi, Aljawharah, Gift, Syna, Grande, Rebecca, Bryson, Mary, Lee, Anna, Dussupt, Vincent, Mendez-Riveria, Letzibeth, Sanders-Buell, Eric, Chenine, Agnès-Laurence, Tran, Ursula, Li, Yifan, Brown, Eric, Edlefsen, Paul T., O’Connell, Robert, Gilbert, Peter, Nitayaphan, Sorachai, Pitisuttihum, Punnee, Rerks-Ngarm, Supachai, Robb, Merlin L., Gramzinski, Robert, Alter, Galit, Tovanabutra, Sodsai, Georgiev, Ivelin S., Ackerman, Margaret E., Polonis, Victoria R., Vasan, Sandhya, Michael, Nelson L., Kim, Jerome H., Eller, Michael A., Krebs, Shelly J., Rolland, Morgane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748270/
https://www.ncbi.nlm.nih.gov/pubmed/33290394
http://dx.doi.org/10.1371/journal.ppat.1009101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748270/
https://www.ncbi.nlm.nih.gov/pubmed/33290394
http://dx.doi.org/10.1371/journal.ppat.1009101

Ejemplares similares